Showing results (1-10 of 290) with videos related to
Sort By:
Pageof 29
Healthcarepapers|July 7, 2023
Canadians Need Improved Access to Drugs for Rare Diseases, Not More DenialNigel S B Rawson, John AdamsThe Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|August 13, 2002
Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United StatesNigel S B RawsonOrphanet Journal of Rare Diseases|March 24, 2017
Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and costNigel S B RawsonRegulatory Toxicology and Pharmacology : RTP|November 5, 2018
Comparison of numbers and timing of new medication regulatory approvals in Canada and New ZealandNigel S B RawsonJournal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|May 8, 2013
New drug approval times and safety warnings in the United States and Canada, 1992-2011Nigel S B RawsonIsrael Journal of Health Policy Research|November 22, 2017
Promoting adherence to medicines: possible lessons for Canada?Nigel S B RawsonInternational Journal of Health Policy and Management|July 3, 2020
National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare"Nigel S B RawsonJournal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|April 20, 2019
Response to Letter to the EditorNigel S B RawsonJournal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|March 4, 2020
Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?Nigel S B RawsonRegulatory Toxicology and Pharmacology : RTP|May 18, 2005
Assessing prescription medications for priority regulatory reviewNigel S B RawsonPageof 29